| Literature DB >> 34127014 |
Krzysztof Durkalec-Michalski1,2, Krzysztof Kusy3, Natalia Główka4, Jacek Zieliński3.
Abstract
BACKGROUND: This study aimed to investigate the effect of multi-ingredient intra- (BA) versus extra- (ALK) cellular buffering factor supplementation, combined with the customary intake of branched-chain amino acids (BCAA) and creatine malate (TCM), on body composition, exercise variables, and biochemical and hematological parameters in 9 elite taekwondo athletes.Entities:
Keywords: Combat sports; Ergogenic support; Exercise capacity; Sport; Supplements
Mesh:
Substances:
Year: 2021 PMID: 34127014 PMCID: PMC8204562 DOI: 10.1186/s12970-021-00451-3
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Fig. 1A flow chart of the study design. Abbreviations: ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; DXA Dual X-ray Absorptiometry; Pre-EX pre-exercise values; T-T the order of laboratory visits and tests (form 1st to 4th visit)
Detailed supplementation characteristics of the examined athletes
| BA | ALK | ||||
|---|---|---|---|---|---|
| Ingredient | Total daily doses | Ingredient | Total daily doses | ||
| Individual dose | Whole group (g·day− 1) | Individual dose | Whole group (g·day− 1) | ||
| Mean ± SD | Mean ± SD | ||||
| BCAA | 0.20 g·kgFFM−1 | 11.0 ± 2.2 | BCAA | 0.2 g·kgFFM−1 | 11.0 ± 2.2 |
| TCM | 0.05 g·kgFFM−1 | 2.8 ± 0.6 | TCM | 0.05 g·kgFFM−1 | 2.8 ± 0.6 |
| Βeta-alanine | 5.0 g | 5.0 | Sodium bicarbonate | 0.07 g·kgFFM−1 | 3.9 ± 0.7 |
| Sodium citrate | 0.75 g | 0.75 | Potassium bicarbonate | 0.07 g·kgFFM−1 | 3.9 ± 0.7 |
| L-histidine HCl | 2.5 g | 2.5 | Calcium phosphate | 0.03 g·kgFFM−1 | 1.7 ± 0.3 |
| Vitamin B6 | 1.75 mg | 0.00175 | Potassium citrate | 0.025 g·kgFFM−1 | 1.4 ± 0.3 |
| Magnesium citrate | 0.025 g·kgFFM−1 | 1.4 ± 0.3 | |||
| Calcium citrate | 0.018 g·kgFFM−1 | 1.0 ± 0.2 | |||
| Magnesium oxide | 0.006 g·kgFFM−1 | 0.3 ± 0.1 | |||
Abbreviations: ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BCAA branched-chain amino acids; FFM fat-free mass; SD standard deviation; TCM creatine malate
Baseline anthropometric, training, and diet characteristics of the examined athletes
| BA→ALK group | ALK→BA group | BA→ALK vs. | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean | ± | SD | Mean | ± | SD | |||
| N | 5 | 4 | - | |||||
| Age | (years) | 21 | ± | 3 | 19 | ± | 3 | 0.27 |
| Body height | (cm) | 181 | ± | 6 | 179 | ± | 10 | 0.60 |
| Body mass | (kg) | 68.1 | ± | 1.2 | 70.2 | ± | 14.5 | 0.75 |
| Fat mass | (kg) | 13.8 | ± | 5.6 | 14.5 | ± | 3.6 | 1.00 |
| Fat-free mass | (kg) | 54.2 | ± | 5.5 | 56.2 | ± | 16.9 | 0.81 |
| V̇O2max | (L·min−1) | 3.65 | ± | 0.67 | 3.68 | ± | 1.09 | 0.95 |
| Training experience | (years) | 8 | ± | 1 | 9 | ± | 3 | 0.52 |
| Energy intake | (kcal·day−1) | 2343 | ± | 492 | 2796 | ± | 472 | 0.20 |
| (kcal·kg−1) | 35.1 | ± | 7.3 | 41.6 | ± | 14.0 | 0.39 | |
| Protein intake | (g·day−1) | 109 | ± | 19 | 111 | ± | 15 | 0.86 |
| (g·kg−1) | 1.6 | ± | 0.3 | 1.6 | ± | 0.5 | 0.71 | |
| (% of energy) | 18.9 | ± | 3.1 | 16.2 | ± | 2.9 | 0.21 | |
| Fat intake | (g·day−1) | 71 | ± | 27 | 106 | ± | 42 | 0.17 |
| (g·kg−1) | 1.1 | ± | 0.4 | 1.6 | ± | 0.7 | 0.21 | |
| (% of energy) | 26.6 | ± | 6.1 | 33.1 | ± | 10.6 | 0.28 | |
| Carbohydrate intake | (g·day−1) | 338 | ± | 60 | 379 | ± | 57 | 0.33 |
| (g·kg−1) | 5.1 | ± | 0.9 | 5.7 | ± | 2.0 | 0.56 | |
| (% of energy) | 58.1 | ± | 3.4 | 55.0 | ± | 9.1 | 0.51 | |
Values are expressed as means ± standard deviation (SD). Abbreviations: ALK multi-ingredient extra-cellular buffering supplement; ALK→BA group the order of implementing the supplementation, 1st ALK, 2nd BA after wash-out; BA multi-ingredient intra-cellular buffering supplement; BA→ALK group the order of implementing the supplementation, 1st BA, 2nd ALK after wash-out; V̇O maximal oxygen uptake
Body mass and composition in taekwondo athletes before and after supplementation
| BA | ALK | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | ± | SD | 95% CI | Mean | ± | SD | 95% CI | |||||||
| Body mass | (kg) | Before | 68.0 | ± | 9.9 | 60.4 | - | 75.6 | 67.0 | ± | 9.0 | 60.1 | - | 73.9 |
| After | 69.1 | ± | 9.3 | 62.0 | - | 76.3 | 69.0 | ± | 8.7 | 62.3 | - | 75.6 | ||
| BMI | (kg∙m−2) | Before | 21.1 | ± | 2.3 | 19.3 | - | 22.8 | 20.7 | ± | 2.1 | 19.1 | - | 22.3 |
| After | 21.4 | ± | 2.1 | 19.8 | - | 23.1 | 21.4 | ± | 2.1 | 19.7 | - | 23.0 | ||
| Total Fat Mass | (kg) | Before | 12.6 | ± | 4.0 | 9.5 | - | 15.8 | 12.6 | ± | 3.9 | 9.6 | - | 15.6 |
| After | 13.8 | ± | 3.9 | 10.8 | - | 16.8 | 14.1 | ± | 4.6 | 10.5 | - | 17.6 | ||
| Total Fat-Free Mass | (kg) | Before | 55.5 | ± | 12.2 | 46.1 | - | 64.8 | 54.9 | ± | 11.2 | 46.3 | - | 63.5 |
| After | 55.8 | ± | 11.2 | 47.2 | - | 64.4 | 55.4 | ± | 11.4 | 46.6 | - | 64.1 | ||
Data are the means ± standard deviation (SD) and 95% confidence intervals (CI). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; BMI body mass index.
Pre-exercise and exercise cardiorespiratory variables in taekwondo athletes before and after supplementation
| BA | ALK | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | ± | SD | 95% CI | Mean | ± | SD | 95% CI | |||||||
| V̇EPre-EX | (L∙min−1) | Before | 14.0 | ± | 2.5 | 12.1 | - | 16.0 | 14.1 | ± | 2.0 | 12.6 | - | 15.7 |
| After | 13.9 | ± | 2.8 | 11.7 | - | 16.0 | 15.9 | ± | 2.8 | 13.7 | - | 18.0 | ||
| HRPre-EX | (bpm) | Before | 83 | ± | 13 | 73 | - | 93 | 80 | ± | 13 | 70 | - | 90 |
| After | 83 | ± | 12 | 73 | - | 92 | 85 | ± | 13 | 75 | - | 95 | ||
| V̇O2Pre-EX | (L∙min−1) | Before | 0.49 | ± | 0.09 | 0.42 | - | 0.56 | 0.47 | ± | 0.07 | 0.42 | - | 0.53 |
| After | 0.48 | ± | 0.07 | 0.43 | - | 0.54 | 0.56 | ± | 0.11 | 0.47 | - | 0.65 | ||
| RERPre-EX | Before | 0.79 | ± | 0.04 | 0.76 | - | 0.83 | 0.83 | ± | 0.05 | 0.79 | - | 0.87 | |
| After | 0.81 | ± | 0.08 | 0.75 | - | 0.88 | 0.81 | ± | 0.08 | 0.75 | - | 0.86 | ||
| V̇EVT | (L∙min−1) | Before | 68.7 | ± | 20.5 | 53.0 | - | 84.5 | 67.1 | ± | 19.7 | 52.0 | - | 82.3 |
| After | 65.9 | ± | 17.5 | 52.4 | - | 79.4 | 68.0 | ± | 17.8 | 54.2 | - | 81.7 | ||
| HRVT | (bpm) | Before | 161 | ± | 15 | 150 | - | 173 | 158 | ± | 15 | 147 | - | 170 |
| After | 159 | ± | 15 | 148 | - | 171 | 161 | ± | 18 | 147 | - | 174 | ||
| V̇O2VT | (L∙min−1) | Before | 2.55 | ± | 0.68 | 2.03 | - | 3.08 | 2.59 | ± | 0.70 | 2.05 | - | 3.13 |
| After | 2.56 | ± | 0.58 | 2.11 | - | 3.01 | 2.64 | ± | 0.59 | 2.18 | - | 3.09 | ||
| RERVT | Before | 0.90 | ± | 0.05 | 0.86 | - | 0.94 | 0.91 | ± | 0.04 | 0.88 | - | 0.95 | |
| After | 0.89 | ± | 0.08 | 0.83 | - | 0.96 | 0.89 | ± | 0.05 | 0.85 | - | 0.93 | ||
| V̇Emax | (L∙min−1) | Before | 129 | ± | 30 | 106 | - | 152 | 129 | ± | 31 | 106 | - | 153 |
| After | 127 | ± | 31 | 104 | - | 151 | 129 | ± | 30 | 106 | - | 152 | ||
| HRmax | (bpm) | Before | 189 | ± | 14 | 178 | - | 200 | 192 | ± | 11 | 183 | - | 200 |
| After | 193 | ± | 12 | 184 | - | 202 | 193 | ± | 10 | 186 | - | 201 | ||
| V̇O2max | (L∙min−1) | Before | 3.64 | ± | 0.84 | 2.99 | - | 4.29 | 3.54 | ± | 0.77 | 2.95 | - | 4.14 |
| After | 3.66 | ± | 0.82 | 3.03 | - | 4.29 | 3.68 | ± | 0.86 | 3.02 | - | 4.33 | ||
| RERmax | Before | 1.10 | ± | 0.05 | 1.06 | - | 1.13 | 1.10 | ± | 0.03 | 1.07 | - | 1.13 | |
| After | 1.06 | ± | 0.07 | 1.01 | - | 1.11 | 1.09 | ± | 0.06 | 1.05 | - | 1.14 | ||
Data are the means ± standard deviation (SD) and 95% confidence intervals (CI). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; HR heart rate; max maximum values; Pre-EX pre-exercise values; RER respiratory exchange ratio; V̇E minute ventilation; V̇O oxygen uptake; VT ventilatory threshold. No significant differences reported (p > 0.05).
The level of exercise blood biomarkers and hematological parameters in taekwondo athletes before and after supplementation (pre-exercise, maximum, and recovery values)
| BA | ALK | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | ± | SD | 95% CI | Mean | ± | SD | 95% CI | |||||||
| LAPre-EX | (mmol∙L−1) | Before | 1.07 | ± | 0.19 | 0.92 | - | 1.21 | 1.18 | ± | 0.27 | 0.97 | - | 1.39 |
| After | 1.13 | ± | 0.26 | 0.93 | - | 1.33 | 1.10 | ± | 0.30 | 0.88 | - | 1.33 | ||
| LAmax | (mmol∙L−1) | Before | 10.9 | ± | 1.6 | 9.7 | - | 12.1 | 10.9 | ± | 2.1 | 9.3 | - | 12.5 |
| After | 10.2 | ± | 1.4 | 9.1 | - | 11.3 | 10.7 | ± | 1.9 | 9.2 | - | 12.2 | ||
| LAR5 | (mmol∙L−1) | Before | 10.33 | ± | 1.64 | 9.07 | - | 11.59 | 9.99 | ± | 1.50 | 8.83 | - | 11.14 |
| After | 9.57 | ± | 1.65 | 8.31 | - | 10.84 | 9.60 | ± | 1.55 | 8.41 | - | 10.79 | ||
| LAR20 | (mmol∙L−1) | Before | 6.37 | ± | 1.77 | 5.01 | - | 7.73 | 6.27 | ± | 1.66 | 4.99 | - | 7.54 |
| After | 5.80 | ± | 1.44 | 4.69 | - | 6.90 | 5.91 | ± | 1.60 | 4.68 | - | 7.14 | ||
| LAR30 | (mmol∙L−1) | Before | 4.63 | ± | 1.58 | 3.42 | - | 5.85 | 4.21 | ± | 1.51 | 3.05 | - | 5.36 |
| After | 4.13 | ± | 1.19 | 3.21 | - | 5.04 | 3.93 | ± | 1.33 | 2.91 | - | 4.96 | ||
| NH3Pre-EX | (μmol∙L−1) | Before | 22.7 | ± | 1.9 | 21.2 | - | 24.1 | 22.6 | ± | 2.3 | 20.8 | - | 24.3 |
| After | 20.8 | ± | 1.9* | 19.4 | - | 22.2 | 21.6 | ± | 2.4 | 19.7 | - | 23.4 | ||
| NH3max | (μmol∙L−1) | Before | 80.3 | ± | 10.6 | 72.2 | - | 88.5 | 81.4 | ± | 8.7 | 74.8 | - | 88.1 |
| After | 72.4 | ± | 10.2** | 64.6 | - | 80.3 | 74.2 | ± | 8.9 *** | 67.4 | - | 81.0 | ||
| NH3R5 | (μmol∙L−1) | Before | 66.4 | ± | 15.9 | 54.2 | - | 78.7 | 69.2 | ± | 11.4 | 60.4 | - | 78.0 |
| After | 61.1 | ± | 17.8 | 47.4 | - | 74.8 | 61.8 | ± | 8.7 | 55.1 | - | 68.5 | ||
| NH3R20 | (μmol L−1) | Before | 48.2 | ± | 11.5 | 39.4 | - | 57.1 | 48.8 | ± | 6.8 | 43.6 | - | 54.0 |
| After | 43.9 | ± | 12.4 | 34.3 | - | 53.4 | 44.4 | ± | 6.3 | 39.6 | - | 49.3 | ||
| NH3R30 | (μmol∙L−1) | Before | 38.8 | ± | 6.5 | 33.8 | - | 43.8 | 37.8 | ± | 4.4 | 34.4 | - | 41.1 |
| After | 34.8 | ± | 8.5 | 28.2 | - | 41.3 | 33.6 | ± | 4.6 | 30.0 | - | 37.1 | ||
| WBCPre-EX | (x109∙L−1) | Before | 5.88 | ± | 1.32 | 4.86 | - | 6.89 | 5.76 | ± | 0.98 | 5.00 | - | 6.51 |
| After | 5.27 | ± | 0.98 | 4.51 | - | 6.02 | 5.06 | ± | 0.80 | 4.44 | - | 5.67 | ||
| LymPre-EX | (x109∙L−1) | Before | 1.74 | ± | 0.24 | 1.56 | - | 1.93 | 1.76 | ± | 0.36 | 1.48 | - | 2.03 |
| After | 1.91 | ± | 0.19 | 1.77 | - | 2.06 | 1.86 | ± | 0.40 | 1.55 | - | 2.17 | ||
| MonPre-EX | (x109∙L−1) | Before | 0.30 | ± | 0.10 | 0.22 | - | 0.38 | 0.41 | ± | 0.15 | 0.30 | - | 0.52 |
| After | 0.38 | ± | 0.15 | 0.26 | - | 0.49 | 0.39 | ± | 0.13 | 0.29 | - | 0.49 | ||
| GraPre-EX | (x109∙L−1) | Before | 3.81 | ± | 1.28 | 2.83 | - | 4.79 | 3.60 | ± | 0.79 | 2.99 | - | 4.21 |
| After | 2.98 | ± | 0.82 | 2.35 | - | 3.60 | 2.81 | ± | 0.58 | 2.37 | - | 3.26 | ||
| RBCPre-EX | (x1012∙L−1) | Before | 4.68 | ± | 0.50 | 4.29 | - | 5.06 | 4.96 | ± | 0.53 | 4.55 | - | 5.38 |
| After | 4.60 | ± | 0.39 | 4.30 | - | 4.90 | 4.65 | ± | 0.38 | 4.36 | - | 4.95 | ||
| HbPre-EX | (mmol∙L−1) | Before | 8.60 | ± | 0.86 | 7.94 | - | 9.27 | 8.78 | ± | 0.64 | 8.28 | - | 9.27 |
| After | 8.47 | ± | 0.84 | 7.83 | - | 9.12 | 8.36 | ± | 0.43 | 8.03 | - | 8.69 | ||
| HtPre-EX | (L∙L−1) | Before | 0.40 | ± | 0.04 | 0.37 | - | 0.43 | 0.41 | ± | 0.03 | 0.39 | - | 0.44 |
| After | 0.40 | ± | 0.03 | 0.37 | - | 0.42 | 0.39 | ± | 0.02 | 0.38 | - | 0.41 | ||
Data are mean ± standard deviation (SD) and 95% confidence intervals (CI). *,**,***: significant difference between “Before” and “After” values (* p=0.006, ** p= 0.013, *** p=0.027). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; Gra granulocytes; Hb hemoglobin; Ht hematocrit; LA lactate; Lym lymphocytes; Mon monocytes; NH ammonia; Pre-EX pre-exercise values; R post-exercise recovery period (5, 20, 30 = minute of recovery); RBC red blood cells; TCM creatine malate; WBC white blood cells
Fig. 2Blood ammonia (NH3) concentration during the post-exercise recovery before and after supplementation. Data are the means ± standard deviation (SD) and individual results. *,**,***: significant difference between “Before” and “After” values (* p = 0.006, ** p = 0.013, *** p = 0.027). Abbreviations: After after supplementation; ALK multi-ingredient extra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; BA multi-ingredient intra-cellular buffering supplement, combined with branched-chain amino acids and creatine malate; Before before supplementation; max maximum value after exercise; Pre-EX pre-exercise values